Advancing curative therapies for rare immune and neurodegenerative diseases
Hematopoietic Stem Cell Lentiviral Gene Therapy is an industrialized clinical reality. By harnessing the source of all immune lineages, we unlock a self-renewing reservoir with the capacity to reach tissues throughout the body.
Clinical success in Hematopoietic Stem Cell Gene Therapy is defined by highly regulated and specific gene expression. Our expertise lies in the masterful engineering of expression Cassettes that drive gene activity within defined safe and efficacious therapeutic window.
X-Linked Agammaglobulinemia (XLA) is a severe primary immunodeficiency caused by mutations in the BTK gene.
NOGA-102 is a precision HSC gene therapy designed to restore BTK expression specifically within the B-cell lineage.
Strategic collaboration with the NIH (Prof. Harry Malech), towards clinical phase I.
Reach out to our team to learn more about our mission.
Thank you. We will contact you shortly.
